Introduction: In the Liraglutide Effect and Action in Diabetes (LEAD) randomized clinical trials (RCTs) assessing liraglutide in type 2 diabetes mellitus (T2DM), glycated hemoglobin (A1c) was reduced by 7-16 mmol/ mol and weight by up to 3.4 kg. As real-life efficacy data on liraglutide is limited, the authors assessed clinical effects in a real-life cohort. Methods: In this retrospective analysis from the Israeli Health Maintenance Organization Maccabi, of patients with T2DM, treated with liraglutide C6 months during 2011-2012, evaluations were performed at baseline and 6 months. Results: Insulin-naïve patients (n = 1,101) treated with liraglutide with at least one A1c or weight measurement were identified. In 933 patients with an additional A1c value after 6 months, A1c decreased by 9 mmol/mol (p\0.0001, 95% CI 7-11) from 72 mmol/ mol. In patients receiving [2 oral antidiabetic drugs (OADs) prior to liraglutide treatment (80.7% patients), A1c decreased by 7 mmol/mol, and in those receiving B2 OADs, by 12 mmol/mol. In 453 patients with baseline data available, weight decreased by 2.55 kg (p\0.0001); 173 patients (38.18%) achieved C1% A1c reduction. Furthermore, 91 patients (20.1%) achieved National Institute for Health and Care Excellence (NICE) criteria (decreased A1c C1%; weight C3%). Weight reduction was marginally correlated with A1c reduction. Electronic supplementary material The online version of this article (Conclusions: Evidence from real-life use of liraglutide demonstrated clinical effects similar to those demonstrated in RCTs.
INTRODUCTION
Better understanding of the pathophysiology of type 2 diabetes mellitus (T2DM) and the central role of the incretins in glucose metabolism led to the development of glucagon-like peptide 1 (GLP-1) receptor agonists as therapeutic agents [1] . In randomized controlled clinical trials, the use of GLP-1 agonists in patients with T2DM caused a substantial decrease in blood glucose and glycated hemoglobin (A1c) measures, combined with weight loss and a low incidence of hypoglycemia [2, 3] . These merits likely contributed to worldwide acceptance of GLP-1 agonists by physicians and patients alike, despite the need for delivery by injection. In current treatment guidelines, therapy for T2DM
includes GLP-1 agonists as an equal or superior treatment option compared with classic oral agents. The American Diabetes Association/ European Association for the Study of Diabetes (ADA/EASD) position statement includes GLP-1 agonists in one of the five combinations for dual therapy and in four combinations for triple therapy [4] . GLP-1 agonists are the top prioritized class after metformin for monotherapy, dual therapy, and triple therapy in the American Association of Clinical Endocrinologists (AACE) algorithm [5] .
Liraglutide is one of the leading GLP-1 agonist therapeutic options [6] . It is a GLP-1 analog that shares 97% sequence homology to native GLP-1. The addition of a C16 fatty acid side chain enables once-daily dosing of liraglutide by prolonging its duration of action to over 24 h. The safety and efficacy of liraglutide have been well detailed in the phase 3 trials, the Liraglutide Effect and Action in Diabetes (LEAD) program [7] [8] [9] [10] [11] [12] . Data from the LEAD trials have demonstrated that liraglutide effectively improves glycemic control in individuals with T2DM, when used as monotherapy, or in combination, with one or more selected oral antidiabetic drugs (OADs).
Across the trials, mean body weight decreased with liraglutide treatment. Reductions in systolic blood pressure (SBP) and improvements in lipid profiles were also observed across the trials. However, these welldesigned randomized clinical trials (RCTs) conducted under strict inclusion and exclusion criteria provide limited information about the efficacy of liraglutide in selected populations. Moreover, cost-effectiveness issues and limited budget have led payers to impose restrictions on the use of liraglutide that were not part of the patient selection in the RCTs and that may influence the outcome in treated patients. Retrospective insurance-based databases and electronic medical records analyses can provide information and guidance beyond that provided in the clinical trials for both payers and prescribers. Recently, reports on reallife effects of liraglutide have been published, but these are based on a small number of patients in a limited number of clinics [13, 14] . In this study, the authors analyzed the [15, 16] .
Patients
The inclusion criteria to the diabetes registry are all patients who have one or more of the following:
A1c C55.7 mmol/mol, blood 
RESULTS

One thousand one hundred and one patients
fulfilled the inclusion and exclusion criteria and had at least one weight or A1c determination within the specified time frames. For 933 patients, the authors had two measurements of A1c in the appropriate time frame at baseline and 6 months after starting liraglutide treatment. losing 3 kg or more ( Fig. 1 ). Ninety-one patients (20.1%) achieved the National Institute for Health and Care Excellence (NICE) criteria (decrease of A1c C11 mmol/mol and weight reduction C3%). Of note, the correlation between A1c reduction and weight reduction was significant, but of a small magnitude (Pearson correlation 0.1156, p = 0.0139) ( Fig. 2 ).
As can be seen in Table 1 , 80.7% of patients received more than two OADs prior to liraglutide treatment.
The 75.7% of patients who received a DPP-4 inhibitor were further evaluated. Table 2 presents the effect of liraglutide treatment according to the number of OADs received prior to therapy and the association with prior DPP-4 inhibitor treatment. Effect of liraglutide on A1c reduction as well as weight reduction and reduction in BMI remained significant in patients who received more than two OADs prior to starting liraglutide treatment, though the magnitude of A1c reduction was somewhat smaller compared with patients who received two OADs or fewer. Furthermore, even patients previously treated with a DPP-4 inhibitor demonstrated significant A1c, weight and BMI reduction on liraglutide treatment.
Subgroup analyses showed no significant differences in liraglutide's effect by gender, weight, age or diabetes duration. In contrast, there was a significant relation between baseline A1c and A1c reduction (\0.0001), as higher A1c levels were significantly related to a higher reduction in A1c (Fig. 3a ). There were no significant correlations between gender, age, BMI, baseline A1c and diabetes duration and weight reduction (Fig. 3b ).
The authors further tried to assess the variables determining the degree of A1c reduction. In the univariate analysis (Table 3) there was a strong positive correlation between A1c reduction and baseline A1c, and the number of prior OADs. When entering these variables into a multivariate linear regression model, variables that remained significantly correlated to A1c reduction were baseline A1c, cardiovascular comorbidity and the number of prior OADs (Table 4 ). The authors also calculated an additional multivariate model for A1c reduction where, in addition to the above-mentioned variables, the authors also entered baseline LDL, HDL, triglycerides and baseline SBP. These variables did not contribute significantly to the model, but limited significantly the number of patients assessed in the model.
Variables that significantly affected weight reduction in the univariate analyses were baseline weight, and the number of OADs the patient took prior to liraglutide treatment ( Table 5 ). The authors also calculated an additional multivariate linear regression model with a dependent variable of weight reduction. None of the multivariate models created for weight reduction were significant. 
DISCUSSION
In this real-world study, liraglutide was shown to be an effective treatment for diabetes, leading to a 9 mmol/mol reduction in A1c accompanied by 2.55 kg reduction in weight ( Table 2 ). In 55% of these patients, the reduction was at least 11 mmol/mol and a weight reduction of [3 kg was observed in 43% of patients ( Fig. 1) . Twenty percent of patients with full laboratory and weight data achieved the NICE criteria for effectiveness [18] . Information on liraglutide efficacy is mainly based on a series of randomized, controlled clinical registration trials [7] [8] [9] [10] [11] [12] (the LEAD trials) conducted over time periods ranging in duration from 26 to studied across the trials, ranging from those who were treatment-naïve to those who had been failing to achieve glycemic targets using multiple OADs.
In this program, liraglutide was shown to reduce A1c levels by 9-18 mmol/mol from baseline, and weight by up to 3.4 kg [20] .
Patients had disease duration of 7.7 years, and RCTs. This probably reflects the fact that reimbursement was limited to those patients with an A1c greater than 63.9 mmol/mol and a BMI greater than 30 kg/m 2 . Liraglutide effect on A1c in this cohort falls in the lower range of A1c and weight observed in the RCTs probably because this population was not only older with longer disease duration but also received more than two OADs, including DPP-4
inhibitors. The importance of early initiation of liraglutide is underscored by the effect liraglutide had in patients who received prior therapy with B2 OADs (12 mmol/mol and -3 kg). The higher effect in this group is in line with a meta-analysis of the LEAD studies where patients on B1 OAD had a much higher reduction in A1c when compared to patients receiving two OADs (15 vs. 9 mmol/mol on liraglutide 1.2 mg and 17 mmol/mol vs. 13 mol/ mol on liraglutide 1.8 mg treatment [21] ). Moreover, those treated with liraglutide after diet or monotherapy had a better chance to achieve a composite target of A1c\53 mmol/ mol with no weight gain when treated with liraglutide, compared with those who received the GLP-1 agonist after treatment with various combination therapies [22] . It should be emphasized that 75.7% of patients in this cohort had previously taken a DPP-4 inhibitor and were subsequently switched to liraglutide because of deteriorating A1c or a failure to reach therapeutic goals. Despite this, 78% of these patients had a further A1c reduction and in 55% the reduction was at least 11 mmol/mol.
This study is the largest real-life study published so far on use of liraglutide and is based on a large database of a nationwide HMO that reflects the Israeli population. Other smaller studies published to date are in line with the findings of this study. In a study from 16 clinics in Wales, 1,114 patients using GLP-1based therapies were followed for a median of 48 weeks. Of the 256 who received liraglutide 1.2 mg, NICE treatment continuation criteria (C11 mmol/mol HbA1c reduction, C3% weight loss) were met by 32% [13] . A further real-world study followed 166 patients from three clinics [14] . A1c glycated hemoglobin study, it has been found that baseline A1c and number of previous OADs had a significant explanatory role. This is in line with the overall impression that early use of GLP-1 agonists could lead to greater benefits. In the Italian study, the drop in A1c was unrelated to baseline BMI or weight loss, while in this current study there was a small but significant correlation between the degree of weight lost and reduction in A1c. This suggests that most of the drop in A1c is independent of weight change. Rather it seems that when weight loss occurs it may further reduce glucose levels.
A recent review that assessed available evidence from clinical trials regarding the efficacy and safety of GLP-1 agonists in the firstor second-line management of T2DM suggests that the early (i.e., second-line, or, in some cases first-line) use of liraglutide and exenatide is justified on grounds of efficacy and safety [23] .
This study has several limitations. This was a non-interventional observational study, in accordance with the definition applied by the
European
Medicines Agency (Directive 2001/20/EC) [24] . Study-specific patient visits, tests and monitoring were not imposed, and only data originating from routine clinical practice were collected. As data were obtained from observational registries, clinical events may not have been captured in full and patient follow-up was not as tight as would be 
